Learned immunosuppressive placebo response attenuates disease progression in a rodent model of rheumatoid arthritis.
Patients with chronic inflammatory autoimmune diseases benefit from a broad spectrum of immunosuppressive and anti-proliferative medication available today. However, nearly all of these therapeutic compounds have unwanted toxic side effects. Recent knowledge about the neurobiology of placebo responses document that associative learning procedures can be utilized for dose reduction in immunopharmacotherapy while simultaneously maintaining treatment efficacy. An established paradigm of taste-immune conditioning was employed in a disease model of chronic inflammatory autoimmune disease (collagen type II-induced arthritis) in rats, where a novel taste (saccharin; conditioned stimulus/CS) is paired with an injection of the immunosuppressive drug cyclosporine A (CsA); (unconditioned stimulus/US). Following conditioning with three CS/US pairings (acquisition), the animals were immunized with collagen type-II and incomplete Freund adjuvant. Fourteen days later at the first occurrence of clinical symptoms, retrieval started by presenting the CS together with low dose CsA as reminder cues to prevent the conditioned response from being extinguished. This memory-updating stabilized the learned immune response and significantly suppressed disease progression in immunized rats. Clinical arthritis score (p<0.05) and histological inflammatory symptoms (p<0.05) were significantly diminished by learned immunosuppression in combination with low-dose CsA (25%) via β-adrenoceptor-depending mechanisms to the same extent as full dose (100%) pharmacological treatment. These results indicate that learned immunosuppression seemed to be mediated via β-adrenoceptors and might be beneficial as a supportive regimen in the treatment of chronic inflammatory autoimmune diseases by diminishing disease exacerbation.